REMEDY : BNSSG referral pathways & Joint Formulary


Home > Formulary : Adult > Chapters > 7. Obstetrics, Gynaecology and Urinary-tract Disorders >

BNSSG Adult Joint Formulary

7.6 Vaginal and vulval conditions

Last edited: 24-10-2024

7.6.1 Vaginal and vulval infections, bacterial

First line drugs Second line drugs Specialist drugs Secondary care drugs

 

Clindamycin cream (TLS Green)

Metronidazole 0.75% gel (TLS Green)

Dequalinium chloride (Fluomizin® 10mg vaginal tablets) (TLS Amber Specialist Recommended)

  • For treatment of bacterial vaginosis

Dequalinium chloride (Fluomizin® 10mg vaginal tablets) (TLS Red)

  • For treatment of trichomoniasis vaginalis

 

7.6.2 Vaginal and vulval infections, fungal

Clotrimazole 1% cream (TLS Green)

Clotrimazole pessary 500mg (TLS Green)

 

 

7.6.3 Vaginal atrophy

Yes! vaginal moisturiser (TLS Green)

  • For vaginal atrophy in post-menopausal women with oestrogen sensitive conditions for whom topical oestrogens are not suitable i.e. patients with a history of breast or endometrial cancer
  • Use nightly until see a benefit and then twice weekly

Estriol cream 0.1% (TLS Green) 

Estradiol vaginal tablets 10micrograms  (TLS Green) (local use)

Estring® Vaginal Ring (TLS Blue)

  • Reserved for patients who are unable to use vaginal pessaries, or for those who have tried vaginal creams or pessaries for several months without clinical benefit

Imvaggis® Pessary (TLS Blue)

  • 2nd line after vaginal moisturisers for women with oestrogen-sensitive conditions following discussion with oncologist or menopause specialist
  • 4th line for women who have not tolerated other formulary options

Ospemifene® tablets (TLS Amber Specialist Recommended)

For moderate to severe vulvovaginal atrophy in women who have:

  • History of breast cancer for whom low dose estriol (Imvaggis®pessary) is unsuitable or;
  • A significant local allergy to vaginal oestrogens or;
  • For those who have failed to respond to all other formulary options after several months of treatment

Prasterone (DHEA) gel (TLS Red)

  • Reserved for postmenopausal women who are taking an aromatase inhibitor
  • Or as a last line option for women who are intolerant to all other formulary options for VVA due to allergy or issues with absorption.

 

Contact Us

Got a question or comment about the Joint Formulary? 

Please use the email address below to contact us and we will endeavour to respond within 2 working days.